136 related articles for article (PubMed ID: 17513824)
21. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y; Lacouture ME; Su X; Wu S
J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib or gefitinib for non-small-cell lung cancer.
Kaye FJ; Jantz MA; Dallas J
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
[No Abstract] [Full Text] [Related]
23. Erlotinib-associated trichomegaly.
Lane K; Goldstein SM
Ophthalmic Plast Reconstr Surg; 2007; 23(1):65-6. PubMed ID: 17237698
[TBL] [Abstract][Full Text] [Related]
24. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Chou LS; Garey J; Oishi K; Kim E
Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
[TBL] [Abstract][Full Text] [Related]
25. Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Gridelli C; Maione P; Galetta D; Rossi A
J Thorac Oncol; 2007 Jan; 2(1):96-8. PubMed ID: 17410020
[No Abstract] [Full Text] [Related]
26. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
[TBL] [Abstract][Full Text] [Related]
27. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
28. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
Frankfort BJ; Garibaldi DC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
[No Abstract] [Full Text] [Related]
29. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
30. Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Melosky B; Anderson H; Burkes RL; Chu Q; Hao D; Ho V; Ho C; Lam W; Lee CW; Leighl NB; Murray N; Sun S; Winston R; Laskin JJ
J Clin Oncol; 2016 Mar; 34(8):810-5. PubMed ID: 26573073
[TBL] [Abstract][Full Text] [Related]
31. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Lind JS; Smit EF; Grünberg K; Senan S; Lagerwaard FJ
J Thorac Oncol; 2008 Sep; 3(9):1050-3. PubMed ID: 18758310
[TBL] [Abstract][Full Text] [Related]
32. [Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Zhang F; Xing LN
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):873-5. PubMed ID: 19173837
[TBL] [Abstract][Full Text] [Related]
33. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
34. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
35. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
36. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
37. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
38. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
[TBL] [Abstract][Full Text] [Related]
39. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Vergou T; Stratigos AJ; Karapanagiotou EM; Matekovits AE; Dilana KD; Tsimboukis S; Antoniou C; Chasapi V; Syrigos KN
J Am Acad Dermatol; 2010 Aug; 63(2):e56-8. PubMed ID: 20633793
[No Abstract] [Full Text] [Related]
40. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
de Marinis F; Vergnenegre A; Passaro A; Dubos-Arvis C; Carcereny E; Drozdowskyj A; Zeaiter A; Perez-Moreno P; Rosell R
Future Oncol; 2015; 11(3):421-9. PubMed ID: 25675123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]